Cushing’s Syndrome Diagnostics And Therapeutics Market By Product Type (Diagnostics, Drugs); By Diagnostic Type (Hormonal Assays, Imaging); By Therapy Type (Steroidogenesis Inhibitors, Surgery); By Route of Administration (Oral, Injectable); By Region – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032
Cushing’s Syndrome Diagnostics And Therapeutics Market Overview:
The global Cushing’s Syndrome Diagnostics And Therapeutics Market size was estimated at USD 383.04 million in 2025 and is expected to reach USD 658.11 million by 2032, growing at a CAGR of 9.44% from 2025 to 2032. Growth is driven by expanding diagnosis and treatment demand across specialist endocrinology pathways as referral networks improve recognition of hypercortisolism and related comorbidities. Cushings Syndrome Diagnostics And Therapeutics Market demand also strengthens as hospital systems and specialty clinics standardize testing algorithms and adopt longer-duration management approaches for patients requiring ongoing monitoring and medical therapy.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2025
Forecast Period
2026-2032
Cushing’s Syndrome Diagnostics And Therapeutics Market Size 2025
USD 383.04 million
Cushing’s Syndrome Diagnostics And Therapeutics Market, CAGR
9.44%
Cushing’s Syndrome Diagnostics And Therapeutics Market Size 2032
USD 658.11 million
Key Market Trends & Insights
The Cushings Syndrome Diagnostics And Therapeutics Market is projected to rise from USD 383.04 million (2025) to USD 658.11 million (2032) at a 9.44% CAGR (2025–2032).
Drugs held 54.60% share in 2025, reflecting sustained reliance on medical management for patients who are not surgical candidates or require long-term control.
North America accounted for 39.40% share in 2025, supported by high diagnostic intensity, specialist availability, and therapy access across endocrine centers.
Europe captured 27.30% share in 2025, reflecting strong specialist networks and structured care pathways across major markets.
Asia Pacific reached 22.90% share in 2025, supported by rising endocrinology capacity and broader access to hormonal testing and imaging.
Segment Analysis
Cushings Syndrome Diagnostics And Therapeutics Market growth is shaped by the close linkage between biochemical confirmation, localization workflows, and treatment selection. Hormonal testing remains central to initial screening and confirmation, and imaging use typically expands after biochemical evidence supports disease suspicion. Clinical pathways increasingly emphasize protocol-driven follow-up, which sustains repeat testing demand and reinforces the role of diagnostics platforms in specialist settings.
Therapeutic utilization expands as disease complexity and comorbidity burden influence treatment sequencing. Surgery remains an important definitive option for eligible patients, but medication use grows where surgery is delayed, not feasible, or does not fully resolve hypercortisolism. Cushings Syndrome Diagnostics And Therapeutics Market dynamics also reflect the need for long-term monitoring and therapy optimization, which supports recurring demand for both diagnostics and drugs.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Drugs accounted for the largest share of 54.60% in 2025. Drugs lead because medical therapy supports ongoing cortisol control for patients who are not optimal candidates for surgery and for patients requiring management after incomplete surgical resolution. Cushings Syndrome Diagnostics And Therapeutics Market prescribing is reinforced by specialist-driven treatment algorithms and longitudinal follow-up, which sustain repeat utilization. Broader availability through specialty channels and structured monitoring improves persistence and supports expansion of drug adoption in routine endocrine care.
By Diagnostic Type Insights
Hormonal assays and imaging serve complementary roles, with hormonal testing supporting confirmation and imaging supporting localization and treatment planning. Cushings Syndrome Diagnostics And Therapeutics Market demand for hormonal assays is supported by protocolized screening pathways and repeat testing to validate results or monitor therapy response. Imaging demand grows after biochemical confirmation, especially in referral centers managing complex cases. Standardized multidisciplinary workflows increasingly tie testing menus and imaging access to optimized clinical decision-making.
By Therapy Type Insights
Steroidogenesis inhibitors and surgery operate as core modalities within endocrinology pathways, with selection influenced by etiology, severity, and patient suitability. Surgery remains a definitive option for eligible patients, supported by specialist endocrine surgery and pituitary programs. Steroidogenesis inhibitors expand utilization when surgery is delayed, not feasible, or not curative, supporting ongoing disease control. Cushings Syndrome Diagnostics And Therapeutics Market adoption reflects real-world need for flexible sequencing and long-term management across diverse patient profiles.
By Route of Administration Insights
Oral and injectable options are selected based on clinical need, monitoring requirements, tolerability, and care-setting capabilities. Oral regimens can support chronic outpatient management and dose titration, which aligns with endocrinology clinic workflows and follow-up structures. Injectable use is typically associated with specific therapeutic profiles and specialist-directed administration pathways. Cushings Syndrome Diagnostics And Therapeutics Market route preferences are shaped by adherence considerations, patient comorbidities, and payer requirements that influence access and continuity.
Cushing’s Syndrome Diagnostics And Therapeutics Market Drivers
Expanding specialist diagnosis and protocol-based endocrine care
Cushings Syndrome Diagnostics And Therapeutics Market growth is supported by broader clinical awareness of hypercortisolism and related metabolic, cardiovascular, and psychiatric comorbidities. Referral networks increasingly route suspected cases to endocrinology specialists, strengthening diagnostic throughput. Standardized workflows encourage sequential use of hormonal assays and imaging, which expands utilization across the care pathway. Health systems also adopt consistent follow-up practices, reinforcing recurring demand for diagnostic services and therapy optimization.
For instance, Siemens Healthineers offers cortisol testing on its Atellica IM platform, and the Atellica IM 1600 supports up to 440 immunoassay tests per hour with up to 42 onboard assays, helping specialist endocrine laboratories run protocol-based hormone workups more efficiently.
Greater reliance on long-term medical management
Cushings Syndrome Diagnostics And Therapeutics Market demand rises as medical therapy becomes central for patients who cannot undergo surgery or who need control after incomplete outcomes. Chronic management requires dose adjustments, monitoring, and repeated clinical assessment, which sustains drug utilization over longer time horizons. Treatment sequencing often includes bridging therapy, adjuvant management, or recurrence management, strengthening therapy continuity. Specialist-led care models also improve persistence by aligning medication use with structured monitoring.
Upgrades in diagnostic platforms and laboratory standardization
Cushings Syndrome Diagnostics And Therapeutics Market momentum benefits from continued adoption of advanced immunoassay platforms and evolving laboratory quality practices. Health systems prioritize reliability, throughput, and standardized interpretation within endocrine testing menus. Integration of lab information systems and protocol-driven ordering improves operational efficiency and supports broader test accessibility. These changes improve clinical confidence in diagnostic pathways and can increase repeat testing for confirmation and monitoring.
For instance, Roche states that its Elecsys Cortisol II assay has a total assay time of 18 minutes, while the cobas e 801 analytical unit performs up to 300 immunochemistry tests per hour and provides 48 onboard reagent positions, supporting faster and more standardized endocrine testing workflows.
Growth in specialty distribution and access pathways for rare endocrine care
Cushings Syndrome Diagnostics And Therapeutics Market expansion is reinforced by specialty pharmacy distribution, payer authorization frameworks, and increasing concentration of care in dedicated endocrine centers. Structured access pathways improve therapy continuity and support adherence through coordinated monitoring. Patient management programs and coordinated care models reduce fragmentation across testing and therapy steps. This infrastructure improves treatment initiation rates and supports broader access across key healthcare systems.
Cushing’s Syndrome Diagnostics And Therapeutics Market Challenges
Cushings Syndrome Diagnostics And Therapeutics Market growth faces constraints from complex diagnostic pathways and variability in testing interpretation across care settings. False positives, conflicting results, and inconsistent pre-analytical practices can delay confirmation and slow time to treatment. Limited specialist capacity in some geographies increases referral delays, which can reduce diagnostic throughput. Access challenges are amplified when reimbursement and prior authorization increase friction across testing and therapy steps.
Cushings Syndrome Diagnostics And Therapeutics Market adoption is also constrained by therapy tolerability, monitoring intensity, and discontinuation risk in real-world settings. Adverse effect management and frequent follow-up requirements can burden clinics and patients, especially in lower-resource systems. Surgical availability and outcomes depend on center experience, which varies by region and can widen disparities. Fragmented care coordination can reduce persistence and weaken long-term management consistency.
For instance, Recordati’s ISTURISA (osilodrostat) normalized mean urinary free cortisol in 77% of patients at 12 weeks versus 8% with placebo in Phase III LINC 4, with 81% maintaining control by week 36; however, it still requires close monitoring for hypocortisolism and adrenal insufficiency, and common adverse reactions reported in over 20% of patients include adrenal insufficiency, fatigue, and nausea.
Cushing’s Syndrome Diagnostics And Therapeutics Market Trends and Opportunities
Cushings Syndrome Diagnostics And Therapeutics Market opportunity expands as endocrine centers strengthen multidisciplinary models that integrate lab testing, imaging, surgery, and medical therapy within unified protocols. Standardized clinical pathways can raise diagnosis rates, reduce delays, and increase continuity of monitoring. Digitized ordering and decision support can support guideline-aligned testing and improve efficient sequencing across diagnostic steps. These care model shifts can raise utilization across both diagnostics and therapeutics.
For instance, Roche’s Generation II automated salivary cortisol assay, evaluated in 52 patients, delivered an area under the curve of 0.956, with 100% sensitivity and 93.2% specificity at a 7 nmol/L cutoff, showing how standardized hormone testing can improve screening accuracy and support more efficient diagnostic workflows in suspected Cushing’s syndrome.
Cushings Syndrome Diagnostics And Therapeutics Market trends also include broader adoption of patient-centric management, with closer monitoring of comorbidities and therapy response in outpatient settings. Improved specialty distribution, coordinated follow-up, and adherence support can strengthen treatment persistence. Growth opportunities are strongest where healthcare systems expand endocrinology capacity and improve access to reliable hormonal assays and imaging. Ongoing innovation in therapy approaches also supports portfolio expansion within specialist-driven care.
Regional Insights
North America (39.40% share, 2025)
Cushings Syndrome Diagnostics And Therapeutics Market leadership in North America, with a 39.40% share in 2025, reflects high diagnostic intensity, broad access to endocrinologists, and strong uptake of specialty therapies. The region benefits from structured referral pathways that connect primary care, hospital networks, and endocrine specialty centers. Diagnostic adoption is supported by robust laboratory infrastructure and access to advanced imaging for localization and pre-surgical planning. Longitudinal care models strengthen repeat testing and sustained therapy utilization across managed pathways.
Europe (27.30% share, 2025)
Cushings Syndrome Diagnostics And Therapeutics Market performance in Europe, holding a 27.30% share in 2025, is supported by strong specialist networks, established tertiary referral centers, and structured clinical pathways. Health systems emphasize standardized diagnostic workups, which supports consistent use of hormonal testing and imaging for confirmation and localization. Reimbursement frameworks can support access to specialty therapies, although cost controls can influence the pace of uptake for premium treatments. Concentration of expertise in major markets supports stable demand across diagnostics and therapeutics.
Asia Pacific (22.90% share, 2025)
Cushings Syndrome Diagnostics And Therapeutics Market expansion in Asia Pacific, with a 22.90% share in 2025, is supported by rising endocrinology capacity, improving access to testing, and broader availability of imaging within large hospital systems. Urban tertiary centers drive adoption as patient identification and referral pathways strengthen. Growth is reinforced by expanding laboratory automation and increased use of structured diagnostic algorithms in large healthcare networks. Access differences across countries remain, but improving specialty care availability supports continued share expansion.
Latin America (6.10% share, 2025)
Cushings Syndrome Diagnostics And Therapeutics Market demand in Latin America, accounting for a 6.10% share in 2025, is anchored by major markets where specialty endocrinology and tertiary hospitals concentrate diagnostic and treatment capability. Testing and imaging capacity improvements strengthen diagnosis rates in leading urban centers, supporting utilization of endocrine workflows. However, payer constraints and uneven distribution of specialist care can limit therapy access and continuity. Market growth is supported by gradual expansion of specialty services and improving care coordination.
Middle East & Africa (4.30% share, 2025)
Cushings Syndrome Diagnostics And Therapeutics Market activity in the Middle East & Africa, representing a 4.30% share in 2025, is supported by advanced specialty care availability in select hubs, particularly within well-funded healthcare systems. Diagnostic and therapeutic demand concentrates in referral hospitals that can support biochemical testing, imaging, and specialist follow-up. Broader regional variability in access and reimbursement can limit adoption outside leading centers. Continued investment in specialty infrastructure can improve diagnosis and long-term management reach.
Competitive Landscape
Cushings Syndrome Diagnostics And Therapeutics Market competition reflects a mix of pharmaceutical manufacturers focused on endocrine therapies and diagnostics leaders supporting hormonal testing platforms. Differentiation is shaped by specialty market access, clinical adoption within endocrine centers, and the ability to support protocol-driven diagnosis and monitoring. Commercial success is reinforced by strong specialist engagement, reliable supply, and patient support approaches that improve therapy continuity. Portfolio breadth across endocrine care and strength in healthcare relationships influence long-term positioning.
Novartis participates in the Cushings Syndrome Diagnostics And Therapeutics Market through its broader endocrinology and specialty medicine capabilities and established commercialization infrastructure in rare and complex diseases. Novartis benefits from strong medical affairs execution, which supports specialist education and guideline-aligned adoption. Novartis can also leverage global access experience to support uptake across structured reimbursement environments. Strategic focus on specialist engagement and integrated evidence generation remains important for sustained competitiveness.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In April 2025, Recordati announced that the U.S. FDA approved the supplemental NDA for ISTURISA (osilodrostat) for adults with Cushing’s syndrome whose surgery is not an option or has not been curative. This label expansion moved ISTURISA beyond its earlier indication in Cushing’s disease and strengthened Recordati’s position in the therapeutic segment of the market.
In July 2024, ESTEVE announced that it had completed the acquisition of HRA Pharma Rare Diseases from Perrigo Company plc. Through this acquisition, ESTEVE added Metopirone, Lysodren, and Ketoconazole HRA to its rare-disease portfolio, expanding its presence in treatments linked to Cushing’s syndrome and related endocrine disorders.
In April 2024, Ubie announced a partnership with the Cushing’s Support and Research Foundation to help shorten the diagnosis journey for patients with Cushing’s disease and Cushing’s syndrome. The collaboration was aimed at validating and refining Ubie’s AI symptom-checking platform and directing potential patients to CSRF resources, making it a notable diagnostics-side partnership in this market
Report Scope
Report Attribute
Details
Market size value in 2025
USD 383.04 million
Revenue forecast in 2032
USD 658.11 million
Growth rate (CAGR)
9.44% (2025–2032)
Base year
2025
Forecast period
2026-2032
Quantitative units
USD million
Segments covered
By Product Type Outlook: Diagnostics, Drugs; By Diagnostic Type Outlook: Hormonal Assays, Imaging; By Therapy Type Outlook: Steroidogenesis Inhibitors, Surgery; By Route of Administration Outlook: Oral, Injectable
Regional scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Key companies profiled
Novartis, Pfizer, Recordati, HRA Pharma, Ipsen, Merck & Co., Johnson & Johnson, Roche, Siemens Healthineers, Abbott
No.of Pages
327
Segmentation
By Product Type
Diagnostics
Drugs
By Diagnostic Type
Hormonal Assays
Imaging
By Therapy Type
Steroidogenesis Inhibitors
Surgery
By Route of Administration
Oral
Injectable
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope
Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology
Executive Summary
Introduction
4.1. Overview
4.2. Key Industry Trends
Global Cushings Syndrome Diagnostics And Therapeutics Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast
Market Breakup by Region
10.1. North America
10.1.1. United States
10.1.1.1. Market Trends
10.1.1.2. Market Forecast
10.1.2. Canada
10.1.2.1. Market Trends
10.1.2.2. Market Forecast
10.2. Europe
10.2.1. Germany
10.2.2. France
10.2.3. United Kingdom
10.2.4. Italy
10.2.5. Spain
10.2.6. Others
10.3. Asia-Pacific
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. South Korea
10.3.5. Australia
10.3.6. Others
10.4. Latin America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Others
10.5. Middle East and Africa
10.5.1. Market Trends
10.5.2. Market Breakup by Country
10.5.3. Market Forecast
Porters Five Forces Analysis
13.1. Overview
13.2. Bargaining Power of Buyers
13.3. Bargaining Power of Suppliers
13.4. Degree of Competition
13.5. Threat of New Entrants
13.6. Threat of Substitutes
Price Analysis
Competitive Landscape
15.1. Market Structure
15.2. Key Players
15.3. Profiles of Key Players
15.3.1. Novartis
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. Financials
15.3.1.4. SWOT Analysis
15.3.2. Pfizer
15.3.3. Recordati
15.3.4. HRA Pharma
15.3.5. Ipsen
15.3.6. Merck & Co.
15.3.7. Johnson & Johnson
15.3.8. Roche
15.3.9. Siemens Healthineers
15.3.10. Abbott
Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the market size outlook for the Cushings Syndrome Diagnostics And Therapeutics Market?
The Cushings Syndrome Diagnostics And Therapeutics Market was valued at USD 383.04 million in 2025 and is projected to reach USD 658.11 million by 2032. The outlook reflects expanding diagnosis and long-term management demand.
What is the CAGR for the Cushings Syndrome Diagnostics And Therapeutics Market during 2025–2032?
The Cushings Syndrome Diagnostics And Therapeutics Market is expected to grow at a CAGR of 9.44% during 2025–2032. Growth is supported by improving clinical pathways and therapy access.
What is the largest segment in the Cushings Syndrome Diagnostics And Therapeutics Market?
Drugs is the largest segment, accounting for 54.60% share in 2025. Ongoing medical management needs and structured monitoring reinforce segment leadership.
What factors are supporting growth in the Cushings Syndrome Diagnostics And Therapeutics Market?
Growth is supported by stronger specialist referral networks, protocol-based testing and monitoring, and sustained demand for medical therapy. Expanding endocrine care capacity also improves diagnosis and continuity.
Which companies are leading in the Cushings Syndrome Diagnostics And Therapeutics Market?
Key companies include Novartis, Pfizer, Recordati, HRA Pharma, Ipsen, Merck & Co., Johnson & Johnson, Roche, Siemens Healthineers, and Abbott. Competitive positioning is shaped by specialty access and platform breadth.
Which region leads the Cushings Syndrome Diagnostics And Therapeutics Market?
North America leads with a 39.40% share in 2025. Strong diagnostic infrastructure and specialty therapy access support regional leadership.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The Global Over-the-Counter (OTC) Drugs Market is projected to grow from USD 268,006.09 MN in 2025 to an estimated USD 435,144.94 MN by 2032, with a CAGR of 6.11% from 2025 to 2032.
The global Complementary And Alternative Medicines Market size was estimated at USD 242,339 million in 2025 and is expected to reach USD 346,028 million by 2032, growing at a CAGR of 5.22% from 2025 to 2032.
The global Combination Anti Diabetes Drugs Market size was estimated at USD 1,189 million in 2025 and is expected to reach USD 2,418 million by 2032, growing at a CAGR of 10.67% from 2025 to 2032.
The global Colon Hydrotherapy Market size was estimated at USD 32.21 million in 2025 and is expected to reach USD 42 million by 2032, growing at a CAGR of 3.9% from 2025 to 2032.
The global CircRNA Synthesis Market size was estimated at USD 189.75 million in 2025 and is expected to reach USD 527 million by 2032, growing at a CAGR of 15.7% from 2025 to 2032,
The global Complex Injectables Market size was estimated at USD 26,141 million in 2025 and is expected to reach USD 46,572 million by 2032, growing at a CAGR of 8.6% from 2025 to 2032.
The global Cardiovascular Drugs Market size was estimated at USD 157,413 million in 2025 and is expected to reach USD 212,787 million by 2032, growing at a CAGR of 4.4% from 2025 to 2032.
The global Chronic Obstructive Pulmonary Disease Drugs Market size was estimated at USD 8389 million in 2025 and is expected to reach USD 12448 million by 2032, growing at a CAGR of 5.8% from 2025 to 2032.
The global CDKL5 Deficiency Disorder Market size was estimated at USD 121 million in 2025 and is expected to reach USD 169 million by 2032, growing at a CAGR of 4.89% from 2025 to 2032.
The global Cervical Cancer Diagnostics And Therapeutics Market size was estimated at USD 117,657 million in 2025 and is expected to reach USD 177,029 million by 2032, growing at a CAGR of 6.01% from 2025 to 2032.
The global chronic lymphocytic leukemia market size was estimated at USD 5,379 million in 2025 and is expected to reach USD 8,304 million by 2032, growing at a CAGR of 6.4% from 2025 to 2032
The global Castrate Resistant Prostate Cancer Therapeutics Market size was estimated at USD 14005 million in 2025 and is expected to reach USD 24791.16 million by 2032, growing at a CAGR of 8.5% from 2025 to 2032.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
